Released Aug 11, 2026, before the open
10-Q filed Aug 11, 2026, 42 days after period end · 0001171843-26-005425
Q2 2026 · 10-Q
Revenue$22.73M$22.73M +11.1% vs Q2 2025+9.5% vs Q1 2026
Net Income-$2.91M-$2.91M N/M vs Q2 2025N/M vs Q1 2026
EPS Diluted-$0.64-$0.64 N/M vs Q2 2025N/M vs Q1 2026
Gross Profit$12,630,000+9.5%
Operating Income-$978,000N/M
Operating Cash Flowderived$325,000−88.2%
Free Cash Flowderived-$363,000N/M
Margins · derived
Gross margin55.6%−0.8 pt vs Q2 2025
Operating margin-4.3%−0.3 pt vs Q2 2025
Net margin-12.8%−1.6 pt vs Q2 2025
What the release said
The release
Same quarter
| Metric | Q2 2026 | Q2 2025 | Q2 2024 | Q2 2023 |
|---|---|---|---|---|
| Revenue | $22.73M | $20.45M | $23.10M | $28.76M |
| Net Income | -$2.91M | -$2.28M | -$2.93M | -$980.00K |
| EPS Diluted | -$0.64 | -$0.52 | -$0.07 | -$0.02 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Harvard Bioscience Inc · CIK 1123494 · Engraved from SEC EDGAR